Pubblicazioni

Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer  (2025)

Autori:
Speltri, Giorgia; Badrane, Ilham; Napolitano, Rebecca; Boschi, Alessandra; Uccelli, Licia; Filippi, Luca; Guidoboni, Massimo; Brunelli, Matteo; Lancia, Federica; Martini, Petra; Iudicello, Antonella; Cittanti, Corrado; Bartolomei, Mirco; Urso, Luca
Titolo:
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer
Anno:
2025
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Referee:
No
Nome rivista:
MOLECULAR DIAGNOSIS & THERAPY
ISSN Rivista:
1177-1062
N° Volume:
29
Numero o Fascicolo:
4
Intervallo pagine:
453-463
Parole chiave:
NECTIN-4
Breve descrizione dei contenuti:
: Nectin cell adhesion molecule 4 (Nectin-4) is specifically overexpressed in most cancers of epithelial origin but downregulated in normal tissue, representing an ideal target for positron emission tomography imaging. The development of positron emission tomography imaging probes targeting Nectin-4 has gained significant attention in recent years, especially after the approval in December 2019 by the US Food and Drug Administration of enfortumab vedotin-an antibody drug conjugate targeting Nectin-4-in patients with locally advanced or metastatic bladder cancer. This article aims to comprehensively review original research articles discussing preclinical development or early translational clinical applications of radiolabeled probes targeting Nectin-4. The main radioactive compounds investigated belong to two classes, antibody-based radiopharmaceuticals and peptide-drug conjugates, in particular novel bicyclic peptides. While monoclonal antibody-based probes have demonstrated theranostic potential in preclinical studies, their clinical application has been hindered by their slow pharmacokinetic properties. However, peptide-based positron emission tomography/computed tomography tracers offer several advantages, such as ease of handling in synthesis, a more favorable biodistribution, and lower immunogenicity and have been tested in preliminary clinical experiences.
Note:
Epub 2025 Jun 5
Id prodotto:
146265
Handle IRIS:
11562/1164351
ultima modifica:
9 luglio 2025
Citazione bibliografica:
Speltri, Giorgia; Badrane, Ilham; Napolitano, Rebecca; Boschi, Alessandra; Uccelli, Licia; Filippi, Luca; Guidoboni, Massimo; Brunelli, Matteo; Lancia, Federica; Martini, Petra; Iudicello, Antonella; Cittanti, Corrado; Bartolomei, Mirco; Urso, Luca, Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer «MOLECULAR DIAGNOSIS & THERAPY» , vol. 29 , n. 42025pp. 453-463

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro

Attività

Strutture

Condividi